Mathematical biology and medical statistics: Contribution to the understanding of AIDS epidemiology

Statistical Methods in Medical Research

Volumn 10, Issue 2, 2001, Pages 141-154

  Donnelly, C A ^a   Cox, D R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPARATIVE STUDY; DATA BASE; DISEASE TRANSMISSION; EPIDEMIOLOGICAL DATA; HEALTH STATISTICS; HUMAN; INCUBATION TIME; INFORMATION PROCESSING; MATHEMATICAL MODEL; MEDICAL RESEARCH; PATIENT COMPLIANCE; PROFESSIONAL PRACTICE; REVIEW; SEXUAL ORIENTATION; SOCIAL ASPECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMETRY; CLINICAL TRIALS; DATABASES, FACTUAL; DISEASE OUTBREAKS; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PATIENT COMPLIANCE; SEXUAL BEHAVIOR; TIME FACTORS;

EID: 0035027682     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/096228001674031290     Document Type: Review

References (97)

1. Update on acquired immune deficiency syndrome (AIDS) - United States
2. Sexual contact patterns between men and women and the spread of HIV-1 in urban centers in Africa
3. The role of sexual partnership networks in the epidemiology of gonorrhoea
4. The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection
5. Correlation equations and pair approximations for spatial ecologies
6. The influence of concurrent partnerships on the dynamics of HIV/AIDS
7. Concurrent partnerships and the spread of HIV
8. Sampling biases and missing data in explorations of sexual partner networks for the spread of sexually transmitted diseases
9. Mapping a social network of heterosexuals at high risk for HIV infection
10. Sexual partner networks in the transmission of sexually transmitted diseases: An analysis of gonorrhea cases in Sheffield, UK
11. A moment closure model for sexually transmitted disease transmission through a concurrent partnership network
12. More realistic models of bacterial STD transmission dynamics: Sexual partnership, pair models and moment closure
13. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal
14. Statistical analysis of HIV infectivity based on partner studies
15. Epidemiologic evidence for time variation in HIV infectivity
16. Viral load and heterosexual transmission of human immunodeficiency virus type 1
17. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons
18. Plasma viremia in human immunodeficiency virus infection
19. Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations
20. Rate of decline of percentage CD4(+) cells is faster in HIV-1 than in HIV-2 infection
21. Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1
22. Viral dynamics in human immunodeficiency virus type 1 infection
23. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
24. Estimation of HIV dynamic parameters
25. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies
26. On individual and population effectiveness of vaccination
27. High-quality clinical databases: Breaking down barriers
28. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
29. So what's so special about randomisation
30. Commentary: Sources of bias must be controlled
31. Randomized versus historical controls for clinical trials
32. Bias in treatment assignment in controlled clinical trials
33. The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials
34. Randomized, controlled trials, observational studies, and the hierarchy of research designs
35. A comparison of observational and randomized controlled trials
36. Choosing between randomised and non-randomised studies: A systematic review
37. Randomized trials or observational tribulations?
38. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study
39. Disease surveillance and data collection issues in epidemic modeling
40. How many pills do patients with HIV infection take?
41. Antigenic diversity thresholds and the development of AIDS
42. Quasi-species dynamics and the emergence of drug-resistance during zidovudine therapy of HIV-infection
43. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine
44. The dynamics of drug action on the within-host population growth of infectious agents: Melding pharmacokinetics with pathogen population dynamics
45. Adherence and drug resistance: Predictions for therapy outcome
46. Production of resistant HIV mutants during antiretroviral therapy
47. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
48. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
49. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
50. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
51. Predictors of optimal virological response to potent antiretroviral therapy
52. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
53. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
54. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group
55. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
56. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1
57. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
58. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
59. A review of sociobehavioural studies on adherence to antiretroviral treatments: Beyond biomedical models?
60. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease
61. A randomized trial to improve self-management practices of adults with asthma
62. A controlled trial of two forms of self-management education for adults with asthma
63. A critical review of interventions to increase compliance with medication-taking, obtaining medication refills, and appointment-keeping in the treatment of cardiovascular disease
64. Interventions to improve antihypertensive drug adherence: A quantitative review of trials
65. Special issue on noncompliance in clinical trials
66. Marginal structural models versus structural nested models as tools for causal inference
67. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
68. Estimating treatment effects in randomized clinical trials in the presence of non-compliance
69. Intent-to-treat analysis and preventive vaccine efficacy
70. Incubation period of AIDS in patients affected by blood transfusion
71. The distribution of the incubation period for the acquired immunodeficiency syndrome (AIDS)
72. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: A collaborative reanalysis
73. Mortality before and after HIV infection in the complete UK population of haemophiliacs
74. Trends in HIV-1 prevalence and analysis of survival times of infected adults in rural Uganda
75. The overall distribution of survival times for UK AIDS patients
76. Survival with the acquired immunodeficiency syndrome - Experience with 5833 cases in New York City
77. Estimation of the incidence of HIV infection - The back projection method. Appendix 4
78. Estimation of the incidence of HIV infection
79. A method for obtaining short term projections and lower bounds on the size of the AIDS epidemic
80. Surrogate endpoints in clinical trials: Definition and operational criteria
81. Surrogate endpoints
82. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research
83. Some remarks on failure-times, surrogate markers, degradation, wear and the quality of life
84. Some statistical issues in the design of HIV-1 vaccine and treatment trials
85. Biases in prevalent cohorts
86. Surveying sexual attitudes
87. Drugs in British prisons
88. Badgers and bovine TB: Conflicts between conservation and health
89. Where are we now? Where are we going? The demographic impact of HIV/AIDS in South Africa
90. c vaccine trial planned for South Africa